Cover Image
市場調查報告書

倦怠感:開發平台分析

Fatigue - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192586
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
倦怠感:開發平台分析 Fatigue - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 55 Pages
簡介

所謂倦怠感(疲勞感·疲憊·沒精神·無感情等)是指肉體或精神性疲憊虛弱化的狀態。主要的前兆·症狀有肌肉痛和淋巴節的疼痛,慢性(長期的)疲勞,暈眩,頭痛,過敏性,食慾不振等。

本報告提供全球各國治療倦怠感所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

倦怠感概要

治療藥的開發

  • 倦怠感開發中產品:概要
  • 倦怠感開發中產品:比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Biovista Inc.
  • Dimerix Bioscience Pty Ltd
  • Hemispherx Biopharma, Inc.
  • Merz Pharmaceuticals GmbH
  • MultiCell Technologies, Inc.
  • Teva Pharmaceutical Industries Limited

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (lofepramine hydrochloride + phenylalanine)
  • armodafinil
  • DMX-400
  • MRZ-9547
  • rintatolimod
  • Small Molecule for Chronic Fatigue Syndrome

最新開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8223IDB

Summary

Global Markets Direct's, 'Fatigue - Pipeline Review, H2 2016', provides an overview of the Fatigue pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fatigue, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fatigue and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Fatigue
  • The report reviews pipeline therapeutics for Fatigue by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Fatigue therapeutics and enlists all their major and minor projects
  • The report assesses Fatigue therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Fatigue

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Fatigue
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fatigue pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fatigue Overview
  • Therapeutics Development
    • Pipeline Products for Fatigue - Overview
  • Fatigue - Therapeutics under Development by Companies
  • Fatigue - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Fatigue - Products under Development by Companies
  • Fatigue - Companies Involved in Therapeutics Development
    • BioLite, Inc.
    • Biovista Inc.
    • Grifols, S.A.
    • Hemispherx Biopharma, Inc.
    • MultiCell Technologies, Inc.
  • Fatigue - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (lofepramine hydrochloride + phenylalanine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alpha-1 proteinase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLI-1402 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant A1PI - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rintatolimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fatigue - Dormant Projects
  • Fatigue - Product Development Milestones
    • Featured News & Press Releases
      • Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, "Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)" in Expert Review of Clinical Pharmacology
      • Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke
      • Sep 21, 2015: Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome Patients Potentially Predictive of Improved Response to Ampligen
      • Sep 17, 2015: Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study
      • Sep 15, 2015: Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome and Relationship to Disease Symptoms
      • Aug 10, 2015: Hemispherx Enters into an Agreement with myTomorrows for an Early Access Program for Rintatolimod in Europe
      • Jun 25, 2015: Hemispherx Receives the European Patent Office Examining Division's Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen Formulations
      • May 27, 2014: Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen Formulations
      • May 21, 2014: Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets
      • Mar 24, 2014: Hemispherx Biopharma Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference
      • Mar 19, 2014: Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference
      • Mar 10, 2014: Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen to Treat Chronic Fatigue Syndrome in Three Additional Latin America Countries
      • Feb 04, 2013: Hemispherx Biopharma Fails To Win FDA Approval For Its Chronic Fatigue Drug Ampligen
      • Dec 21, 2012: Hemispherx Biopharma Announces Outcome Of FDA Meeting On Ampligen
      • Oct 22, 2012: Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting On December 20, 2012
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Fatigue, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Fatigue - Pipeline by BioLite, Inc., H2 2016
  • Fatigue - Pipeline by Biovista Inc., H2 2016
  • Fatigue - Pipeline by Grifols, S.A., H2 2016
  • Fatigue - Pipeline by Hemispherx Biopharma, Inc., H2 2016
  • Fatigue - Pipeline by MultiCell Technologies, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Fatigue - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Fatigue, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top